{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T11:21:25Z","timestamp":1705404085449},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T00:00:00Z","timestamp":1273622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Loss of heterozygosity (LOH) is an important marker for one of the 'two-hits' required for tumor suppressor gene inactivation. Traditional methods for mapping LOH regions require the comparison of both tumor and patient-matched normal DNA samples. However, for many archival samples, patient-matched normal DNA is not available leading to the under-utilization of this important resource in LOH studies. Here we describe a new method for LOH analysis that relies on the genome-wide comparison of heterozygosity of single nucleotide polymorphisms (SNPs) between cohorts of cases and un-matched healthy control samples. Regions of LOH are defined by consistent decreases in heterozygosity across a genetic region in the case cohort compared to the control cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>DNA was collected from 20 Follicular Lymphoma (FL) tumor samples, 20 Diffuse Large B-cell Lymphoma (DLBCL) tumor samples, neoplastic B-cells of 10 B-cell Chronic Lymphocytic Leukemia (B-CLL) patients and Buccal cell samples matched to 4 of these B-CLL patients. The cohort heterozygosity comparison method was developed and validated using LOH derived in a small cohort of B-CLL by traditional comparisons of tumor and normal DNA samples, and compared to the only alternative method for LOH analysis without patient matched controls. LOH candidate regions were then generated for enlarged cohorts of B-CLL, FL and DLBCL samples using our cohort heterozygosity comparison method in order to evaluate potential LOH candidate regions in these non-Hodgkin's lymphoma tumor subtypes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Using a small cohort of B-CLL samples with patient-matched normal DNA we have validated the utility of this method and shown that it displays more accuracy and sensitivity in detecting LOH candidate regions compared to the only alternative method, the Hidden Markov Model (HMM) method. Subsequently, using B-CLL, FL and DLBCL tumor samples we have utilised cohort heterozygosity comparisons to localise LOH candidate regions in these subtypes of non-Hodgkin's lymphoma. Detected LOH regions included both previously described regions of LOH as well as novel genomic candidate regions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We have proven the efficacy of the use of cohort heterozygosity comparisons for genome-wide mapping of LOH and shown it to be in many ways superior to the HMM method. Additionally, the use of this method to analyse SNP microarray data from 3 common forms of non-Hodgkin's lymphoma yielded interesting tumor suppressor gene candidates, including the ETV3 gene that was highlighted in both B-CLL and FL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-10-195","type":"journal-article","created":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T18:15:22Z","timestamp":1273688122000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A new method to detect loss of heterozygosity using cohort heterozygosity comparisons"],"prefix":"10.1186","volume":"10","author":[{"given":"Michael R","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Jardine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Wellwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rod A","family":"Lea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Marlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyn R","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,12]]},"reference":[{"key":"1994_CR1","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1073\/pnas.70.12.3324","volume":"70","author":"D Comings","year":"1971","unstructured":"Comings D: A general theory of carcinogenesis. Proc Natl Acad Sci. 1971, 70: 3324-3328. 10.1073\/pnas.70.12.3324.","journal-title":"Proc Natl Acad Sci"},{"key":"1994_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/35101031","volume":"1","author":"A Knudson","year":"2001","unstructured":"Knudson A: Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001, 1: 157-163. 10.1038\/35101031.","journal-title":"Nat Rev Cancer"},{"key":"1994_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00001622-200201000-00012","volume":"14","author":"S Thiagalingam","year":"2002","unstructured":"Thiagalingam S, Foy R, Cheng K, Lee H, Thigalingam A, Ponte J: Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr Opin Oncol. 2002, 14: 65-72. 10.1097\/00001622-200201000-00012.","journal-title":"Curr Opin Oncol"},{"key":"1994_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/4447","volume":"21","author":"R Lipshutz","year":"1999","unstructured":"Lipshutz R, Fodor S, Gingeras T, Lockhart D: High density synthetic oligonucleotide arrays. Nat Genet. 1999, 21: 20-24. 10.1038\/4447.","journal-title":"Nat Genet"},{"key":"1994_CR5","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/nar\/gkm076","volume":"35","author":"S Collela","year":"2007","unstructured":"Collela S, Yau C, Taylor J, Mirza G, Butler H, Clouston P, Bassett A, Seller A, Holmes C, Ragoussis J: QuantiSNP: an objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nuceic Acids Res. 2007, 35: 2013-2015. 10.1093\/nar\/gkm076.","journal-title":"Nuceic Acids Res"},{"key":"1994_CR6","doi-asserted-by":"crossref","unstructured":"Wang K, Li M, Hadley D, Liu R, Glessner J, Grant S, Hakonarson H, Bucan M: PennCNV: an integrated Hidden-Markov Model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 17: 1665-1674. 10.1101\/gr.6861907.","DOI":"10.1101\/gr.6861907"},{"key":"1994_CR7","first-page":"323","volume":"2","author":"R Beroukhim","year":"2009","unstructured":"Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway L, Fox E, Hochberg E, Mellinghoff I, Hofer M, Descazeaud A, Rubin M, Meyerson M, Wong W, Sellers W, Li C: Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLOS Comput Biol. 2009, 2: 323-332.","journal-title":"PLOS Comput Biol"},{"key":"1994_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/bioinformatics\/bth069","volume":"20","author":"M Lin","year":"2004","unstructured":"Lin M, Wei L, Sellers W, Lieberfarb M, Wong W, Li C: dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004, 20: 1233-1240. 10.1093\/bioinformatics\/bth069.","journal-title":"Bioinformatics"},{"key":"1994_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1349-7006.2007.00443.x","volume":"98","author":"S Tsuzuki","year":"2007","unstructured":"Tsuzuki S, Karnan S, Horibe K, Matsumoto K, Kato K, Inukai T, Goi K, Sugita K, Nakazawa S, Kasugai Y, Ueda R, Seto M: Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: Analysis by means of array-based comparative genomic hybridization. Cancer Sci. 2007, 98: 698-706. 10.1111\/j.1349-7006.2007.00443.x.","journal-title":"Cancer Sci"},{"key":"1994_CR10","first-page":"594","volume":"84","author":"I Wlodarska","year":"1999","unstructured":"Wlodarska I, Pittaluga S, Hagemeijer H, De Wolf-Peeters C, Berghe Van Den H: Secondary chromosomal changes in mantle cell lymphoma. Haematologica. 1999, 84: 594-599.","journal-title":"Haematologica"},{"key":"1994_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.blre.2008.03.009","volume":"22","author":"H Tran","year":"2008","unstructured":"Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi M: Immunodeficiency-associated lymphomas. Blood Rev. 2008, 22: 261-281. 10.1016\/j.blre.2008.03.009.","journal-title":"Blood Rev"},{"key":"1994_CR12","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1182\/blood-2005-01-026690","volume":"108","author":"D Hill","year":"2006","unstructured":"Hill D, Wang S, Cerhan J, Davis S, Cozen W, Severson R, Hartge P, Wacholder S, Yeager M, Chanock S, Rothman N: Risk of non-Hodgkin's lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood. 2006, 108: 3161-3167. 10.1182\/blood-2005-01-026690.","journal-title":"Blood"},{"key":"1994_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00439-006-0177-2","volume":"119","author":"M Shen","year":"2006","unstructured":"Shen M, Zheng T, Lan Q, Zhang Y, Zahm S, Wang S, Holford T, Leaderer B, Yeager M, Welch R, Kang D, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S, Rothman N: Polymorphisms in DNA repair genes and risk of non- Hodgkin's lymphoma among women in Connecticut. Hum Genet. 2006, 119: 659-668. 10.1007\/s00439-006-0177-2.","journal-title":"Hum Genet"},{"key":"1994_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/1055-9965.EPI-05-0583","volume":"15","author":"K Ekstrom-Smedby","year":"2006","unstructured":"Ekstrom-Smedby K, Lindgren C, Hjalgrim H, Humphreys K, Schollkopf C, Chang E, Roos G, Ryder L, Falk K, Palmgren J, Kere J, Melbye M, Glimelius B, Adami H: Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of Follicular Lymphoma. Cancer Epidemiol Biomarkers Prev. 2006, 15: 258-265. 10.1158\/1055-9965.EPI-05-0583.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1994_CR15","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1182\/blood-2002-01-0278","volume":"100","author":"T Taniguchi","year":"2002","unstructured":"Taniguchi T, Garcia-Higuera I, Andreassen P, Gregory R, Grompe M, D'Andrea A: S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood. 2002, 100: 2414-2420. 10.1182\/blood-2002-01-0278.","journal-title":"Blood"},{"key":"1994_CR16","doi-asserted-by":"publisher","first-page":"50986","DOI":"10.1074\/jbc.M407160200","volume":"279","author":"B Freie","year":"2004","unstructured":"Freie B, Ciccone S, Li X, Plett P, Orschell C, Srour E, Hanenberg H, Shindler D, Lee S, Clapp W: A role for the Fanconi anemia C protein in maintaining the DNA damage-induced G2 checkpoint. J Biol Chem. 2004, 279: 50986-50993. 10.1074\/jbc.M407160200.","journal-title":"J Biol Chem"},{"key":"1994_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/emboj.2008.15","volume":"27","author":"R Hakem","year":"2008","unstructured":"Hakem R: DNA-damage repair; the good, the bad, and the ugly. EMBO J. 2008, 27: 589-605. 10.1038\/emboj.2008.15.","journal-title":"EMBO J"},{"key":"1994_CR18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/sj.onc.1204294","volume":"20","author":"J Bai","year":"2001","unstructured":"Bai J, Brody J, Kadkol S, Pasternack G: Tumor suppression and potentiation by manipulation of pp32 expression. Oncogene. 2001, 20: 2153-2160. 10.1038\/sj.onc.1204294.","journal-title":"Oncogene"},{"key":"1994_CR19","doi-asserted-by":"publisher","first-page":"7215","DOI":"10.4049\/jimmunol.179.11.7215","volume":"179","author":"K El Kasmi","year":"2007","unstructured":"El Kasmi K, Smith A, Williams L, Neale G, Panopolous A, Watowich S, Haker H, Foxwell B, Murray P: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J Immunol. 2007, 179: 7215-7219.","journal-title":"J Immunol"},{"key":"1994_CR20","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/blood-2006-07-034256","volume":"109","author":"D Pfiefer","year":"2007","unstructured":"Pfiefer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martenz U, Fisch P, Timmer J, Veelken H: Genome-wide analysis of DNA copy number and LOH in CLL using high-density SNP arrays. Blood. 2007, 109: 1202-1210. 10.1182\/blood-2006-07-034256.","journal-title":"Blood"},{"key":"1994_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.iy.12.040194.001041","volume":"12","author":"P Baeuerle","year":"1994","unstructured":"Baeuerle P, Henkle T: Function and activation of NFkappa-B in the immune system. Ann Rev Immunol. 1994, 12: 141-179.","journal-title":"Ann Rev Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-195\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T05:57:17Z","timestamp":1630475837000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-195","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,12]]},"assertion":[{"value":"16 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"195"}}